Dr. Huang is a partner of Global Law Office based in Shanghai. Dr. Huang has a particularly strong background in pharmaceutical and healthcare industrial sectors. Her main practice areas are intellectual property and intellectual property dispute resolution , covering Patent Law, Anti-unfair Competition Law. She has over 15 years of experience.

Dr. Huang is one of the few professionals in China who has complete experience and comprehensive knowledge of the pharmaceutical industry, patent infringement litigation, patent invalidation & administrative litigation, trade secret infringement litigation.and patent industrialization. In addition to standard services such as intellectual property dispute resolution, FTO analysis, patentability analysis, patent stability analysis, and patent ownership dispute resolution, Dr. Huang is capable of providing clients with efficient and practical advice in contract negotiations, contract terms design, and resolution of disputes, for her extensive experience in the industry.

Dr. Huang excels at elevating practice to theory, having published numerous academic papers in SCI and CSSCI journals. Her doctoral research, "The Doctrine of Equivalent Infringement under the Dual System" filled a gap in the field of Patent Law research in China.

Dr. Huang joined Global Law Office as a partner in 2023. Prior to joining GLO , Dr.Huang worked at a leading Red Circle law firm.

Dr.Huang worked at Beijing Chest Hospital affiliated to Capital Medical University after graduation from Peking University Medical Center .

Dr. Huang worked at State Intellectual Property Office of China as a patent examiner focusing the field of Pharmaceutical and Biotechnology.

Dr.Huang was once a member of the BD (Business Development) team at Hansoh Pharmaceutical (03692.HK), a leading Chinese pharmaceutical group.

Dr. Huang was responsible for or participated in numerous project evaluations and transactions. Before joining Hansoh Pharmaceutical, Dr. Huang worked at the Shanghai Intellectual Property Court.

Chinese Bar

Chinese Patent Bar

Peking University Medical Center, Master of Biochemistry and Molecular Biology

Shanghai Jiaotong University, Juris Doctor

• Lijun Huang et al: Identification of cis-acting elements in the first intron of the coagulation factor FVIIIA chain, Journal of China Biochemistry and Molecular Biology, 2007, Issue 5.
• Lijun Huang et al: The role of transcription factors Sp1 and YY1 in the proximal promoter region in the initiation of transcription of the mu opioid receptor gene in human lymphocytes, Journal of Cellular Biochemistry, Volume 104, Issue 1: 237–250, 2008. (SCI)
• Lijun Huang et al: Homozygous intronic mutation leading to inefficient transcription combined with a novel frameshift mutation in F13A1 gene causes FXIII deficiency, Journal of Human Genetics 56: 460-463, 2011. (SCI)
• Lijun Huang et al: Research on the consistent implementation of standards for gene clusters during the examination process, Journal of China Invention and Patent, 2012, Issue 10.
• Lijun Huang et al: A preliminary analysis on how to expand the protection scope of gene sequence-related applications, Journal of Innovation Times, 2013, Issue 11.
• Lijun Huang: The patent transformation of the drug Enbrel and its implications for the patent transformation in Chinese universities, Journal of Intellectual Property, 2017, Issue 4. (CSSCI)
• Lijun Huang: University patent transfer and transformation and economic innovation-driven development under the new normal, Journal of Nantong University (Social Sciences Edition), 2017, Issue 11. (CSSCI)
• Lijun Huang et al: Multidimensional considerations on patent quality from the perspective of patent transformation, Journal of China Invention and Patent, 2018, Issue 2.
• Lijun Huang: The scope of claims protection under the dual system, Journal of Law, 2019, Issue 1. (CSSCI)
• Lijun Huang: Comments on the restrictive principles of the doctrine of equivalent infringement and the principle of interference with claims, Journal of Beijing Institute of Technology (Social Sciences Edition) , January 2021. (CSSCI).